Below is a look at some of the headlines for companies that made news in the healthcare sector on May 15, 2014.
Specialty pharma company Lipocine (NASDAQ: LPCN) is out with news on a successful Phase 1 LPCN 1107 result.
According to the company's press release, "LPCN 1107 has the potential to become the first orally bioavailable hydroxyprogesterone caproate indicated for the prevention of preterm birth."
Hydroxyprogesterone caproate is the only drug approved for prevention of recurrent pre-term birth.
The Wall Street Journal reported, "The company expects to report top-line efficacy data for the trial in the second half of 2014 with a New Drug Application ("NDA") filing with the U.S. Food and Drug Administration (FDA) anticipated in the second half of 2015."
Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of locally advanced cutaneous melanoma will be featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting to be held at McCormick Place, Chicago, IL. These presentations show that IL PV-10 (a) can potentially offer cancer patients control of their cutaneous symptoms and (b) elicit a systemic anti-tumor immune response that may lead to response of uninjected lesions (the “bystander effect” that has been observed in prior clinical studies of PV-10).
The first highlighted poster, presented by Sanjiv S. Agarwala, MD, of the St. Luke’s Cancer Center, based upon abstract #132320 (permanent ID 9027), is entitled “Efficacy of intralesional rose bengal in patients receiving injection in all existing melanoma in phase II study PV-10-MM-02.”
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today reported financial results for the quarter ended March 31, 2014.
Amedica Corporation (Nasdaq:AMDA), a commercial biomaterial company focused on using its silicon nitride technology platform to develop, manufacture and sell a broad range of medical devices, today announced financial results for the first quarter ended March 31, 2014.
Analogic Corporation (Nasdaq:ALOG), enabling the world's medical imaging and aviation security technology, shared the announcement of its distribution agreement with D&K Technologies, developer of the BioJet™ solution, a revolutionary 3D MRI transrectal ultrasound (TRUS) fusion technology, at the American Urological Association (AUA) Annual Meeting today in Orlando, Fla.
Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that company chief operating officer Fred Miesowicz, Ph.D., will participate in a panel discussion on manufacturing challenges in the development of cell therapies.
Authentidate Holding Corp. (Nasdaq:ADAT), a provider of secure web-based software applications and telehealth products and services for healthcare organizations, today announced financial results for the three-month and nine-month periods ended March 31, 2014.
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics to prevent and treat diseases, with a primary focus on heart disease, today provided a business and financial update for the first quarter ended March 31, 2014.
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, today reported financial results for the third quarter of fiscal 2014.
Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, today reported financial results for the three months ended March 31, 2014.
Immunomedics, Inc. (Nasdaq:IMMU), today announced that five posters on its product candidates will be presented at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) scheduled for May 30 – June 3, 2014 at the McCormick Place Convention Center in Chicago, Illinois.
IPC The Hospitalist Company, Inc. (Nasdaq:IPCM), a leading national hospitalist physician group practice company, announced today that it has acquired RG Psychological Services, P.C. Headquartered in Lynbrook, New York, RG's practice covers more than 80 post-acute care facilities in the greater New York metropolitan area as well as the Albany market.
Nature's Sunshine Products, Inc. (Nasdaq:NATR), a leading natural health and wellness company engaged in the manufacture and direct selling of nutritional and personal care products, today announced that Gregory Probert, Nature's Sunshine Products' Chairman of the Board and Chief Executive Officer and Stephen Bunker, Executive Vice President, Chief Financial Officer and Treasurer, will participate in B. Riley & Co.'s 15th Annual Investor Conference to be held May 19-21, 2014 at The Loews Santa Monica Beach Hotel in Santa Monica, CA.
The Board of Directors of Navidea Biopharmaceuticals, Inc. (NYSE:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it is refocusing the Company's resources to better align the funding of the pipeline programs with the expected growth in Lymphoseek revenue.
Premier, Inc. (Nasdaq:PINC), a leading healthcare improvement company, today announced that it will host its inaugural Investor Day and Economic Outlook event on Wednesday, May 28, 2014, from 8 a.m. to 1:20 p.m. ET at TKP New York, Inc. of 109 West 39th Street in New York City.
Spine Pain Management, Inc. (OTCQB:SPIN), a technology-driven, medical service, device and healthcare solution company servicing the multi-billion dollar spine injury sector, today announced financial results for the first quarter 2014.
Terra Tech Corp (TRTC), an urban agricultural company, is pleased to announce the filing of its First Quarter 2014 financial results for the quarter ending March 31, 2014.
Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today reported its financial results for the first quarter ended March 31, 2014.
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.
Add this page to your favorite Social Bookmarking websites